Certara (NASDAQ:CERT) Releases Earnings Results, Beats Estimates By $0.03 EPS

Certara (NASDAQ:CERT) issued its earnings results on Thursday. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.03, FiscalAI reports. The company had revenue of $104.62 million for the quarter, compared to analysts’ expectations of $104.53 million. Certara had a return on equity of 5.17% and a net margin of 2.62%.During the same period last year, the business earned $0.13 EPS. Certara updated its FY 2025 guidance to 0.450-0.470 EPS.

Certara Stock Performance

CERT stock traded down $2.60 during midday trading on Friday, hitting $8.67. The company’s stock had a trading volume of 9,104,388 shares, compared to its average volume of 1,604,633. The stock has a market cap of $1.39 billion, a price-to-earnings ratio of 123.86 and a beta of 1.44. The company has a quick ratio of 2.16, a current ratio of 2.16 and a debt-to-equity ratio of 0.27. The stock’s 50-day moving average price is $11.77 and its 200 day moving average price is $11.51. Certara has a 1 year low of $8.47 and a 1 year high of $15.69.

Insider Activity

In other news, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $10.92, for a total transaction of $559,366.08. Following the sale, the insider directly owned 73,979 shares in the company, valued at $807,850.68. The trade was a 40.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.33% of the stock is currently owned by corporate insiders.

Institutional Trading of Certara

A number of large investors have recently added to or reduced their stakes in the stock. Osaic Holdings Inc. boosted its stake in Certara by 50.7% in the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock worth $41,000 after purchasing an additional 1,175 shares during the period. Tower Research Capital LLC TRC lifted its holdings in shares of Certara by 499.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock worth $69,000 after buying an additional 4,930 shares in the last quarter. Canada Pension Plan Investment Board bought a new position in shares of Certara in the second quarter valued at approximately $83,000. Corient Private Wealth LLC grew its stake in Certara by 11.7% during the second quarter. Corient Private Wealth LLC now owns 12,362 shares of the company’s stock valued at $144,000 after acquiring an additional 1,295 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in Certara during the 2nd quarter worth approximately $183,000. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Wall Street Analyst Weigh In

CERT has been the topic of a number of recent research reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Certara in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of Certara from a “hold” rating to a “buy” rating in a report on Saturday. Zacks Research raised shares of Certara from a “strong sell” rating to a “hold” rating in a research report on Friday, September 5th. UBS Group decreased their price objective on Certara from $17.50 to $15.00 and set a “buy” rating for the company in a report on Thursday, August 7th. Finally, Barclays lowered their price objective on Certara from $16.00 to $14.00 and set an “overweight” rating for the company in a research note on Friday. Six research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $15.38.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.